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Background
HCM is the main cause for SCD in adults and evidence
of myocardial fibrosis is associated with poor prognosis.
In 2014, a new risk score to predict SCD within 5 years
has been established for HCM patients by the European
Society of Cardiology (ESC). A score ≥ 6% indicates ICD
implantation according to the current ESC recommen-
dations. We analyzed quantitatively global myocardial
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Figure 1 Correlation of global ECV (R = 0.68, p < 0.01) and global LGE with the SCD Risk Score (R = 0.39, p = 0.08). Dashed lines define
a 95% confidence interval. Continuous line represents the fitting line.
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fibrosis using ECV and LGE measurement in HCM
patients. Correlations and ROC curves were performed
between LGE, ECV and the SCD risk score to evaluate
the value of these quantitative imaging parameters to
predict estimated SCD risk in HCM patients.
Methods
CMR was performed in 62 patients with HCM (53 ± 16
years, 34 men) and 16 healthy volunteers (51,8 ± 9
years, 8 men) using a 1.5T scanner (Achieva,Philips).
Post-contrast images were obtained after injection of
0.075 mmol/kg Gd-BOPTA. Two observers indepen-
dently analyzed fibrosis size on phase-sensitive inver-
sion-recovery (PSIR) LGE-images and on ECV maps.
Mean fibrosis size was assessed on 3 short axes obtained
at the apex, center and basis of the left ventricle (LV)
and expressed in % of LV area (%LV). On LGE images
fibrosis was quantified using a threshold method of
>2SD above normal appearing myocardium. For ECV a
threshold ≥30% was defined, which was >2SD above the
mean ECV of 25.8% ± 4.2% assessed from 16 healthy
volunteers. The SCD risk score was calculated for each
patient. Global LGE and global ECV were correlated
with the risk score. ROC Analysis was used to identify
optimal thresholds and areas under the curves (AUCs)
for a risk score of ≥ 6%. The Youden index was used to
depict optimal cutoff values from the ROC curves.
Results
LGE was present in 66% of HCM patients. The risk score
was not different in patients with and without LGE (p =
0.063), whereas significantly higher scores were present in
patients with a global ECV of ≥30% (p = 0.016). A good
correlation was found between ECV and the risk score
(R = 0.68, p < 0.01) while LGE revealed a lower correlation
with the risk score (R= 0.39, p = 0.08 versus ECV; Fig 1).
ROC-analysis showed that ECV≥ 34.6% had a better AUC
with 0.92, p = 0.002 to predict a risk score of ≥ 6% com-
pared to LGE using a fibrosis size of ≥30.1 %LV as cutoff
with an AUC of 0.74, p = 0.07, Fig. 2).
Conclusions
Global ECV correlated best with the clinical risk score to
predict SCD in HCM patients. Furthermore, global ECV ≥
34.6% had a very good test performance to predict an
increased clinical risk score of ≥ 6% indicating its potential
value for risk stratification in patients with HCM.
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Figure 2 ROC Curves of global ECV and global LGE for
discrimination of HCM patients with a SCD risk score of ≥6%
at 5 years.
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